Chimerix Inc. (CMRX) Sees Unusually-High Trading Volume
Chimerix Inc. (NASDAQ:CMRX) shares saw unusually-high trading volume on Wednesday . Approximately 507,772 shares changed hands during trading, a decline of 5% from the previous session’s volume of 532,702 shares.The stock last traded at $5.01 and had previously closed at $4.76.
CMRX has been the subject of several recent research reports. Zacks Investment Research upgraded shares of Chimerix from a “hold” rating to a “buy” rating and set a $4.75 target price for the company in a report on Wednesday, August 10th. Piper Jaffray Cos. set a $12.00 target price on shares of Chimerix and gave the stock a “buy” rating in a report on Thursday, August 18th. FBR & Co restated a “hold” rating on shares of Chimerix in a report on Sunday, July 17th. Finally, JPMorgan Chase & Co. reiterated a “hold” rating and issued a $7.00 price target on shares of Chimerix in a research note on Tuesday, August 9th. Two investment analysts have rated the stock with a sell rating, ten have assigned a hold rating, two have issued a buy rating and one has given a strong buy rating to the company. Chimerix presently has an average rating of “Hold” and an average target price of $15.72.
The firm’s market cap is $220.90 million. The company has a 50-day moving average price of $4.17 and a 200-day moving average price of $4.90.
Chimerix (NASDAQ:CMRX) last announced its quarterly earnings data on Monday, August 8th. The biopharmaceutical company reported ($0.39) earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of ($0.51) by $0.12. The firm earned $1.80 million during the quarter, compared to the consensus estimate of $1.98 million. On average, equities research analysts anticipate that Chimerix Inc. will post ($1.78) EPS for the current year.
In other news, Director Ernest Mario acquired 50,000 shares of the stock in a transaction that occurred on Friday, June 24th. The shares were acquired at an average cost of $3.70 per share, for a total transaction of $185,000.00. Following the purchase, the director now owns 381,440 shares of the company’s stock, valued at approximately $1,411,328. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, CEO M Michelle Berrey acquired 13,188 shares of the stock in a transaction that occurred on Friday, June 24th. The stock was purchased at an average price of $3.69 per share, for a total transaction of $48,663.72. Following the completion of the purchase, the chief executive officer now directly owns 258,821 shares in the company, valued at approximately $955,049.49. The disclosure for this purchase can be found here.
A number of large investors have recently made changes to their positions in the stock. Schwab Charles Investment Management Inc. boosted its stake in shares of Chimerix by 5.1% in the fourth quarter. Schwab Charles Investment Management Inc. now owns 141,181 shares of the biopharmaceutical company’s stock worth $1,264,000 after buying an additional 6,847 shares in the last quarter. Jennison Associates LLC boosted its stake in shares of Chimerix by 67.9% in the fourth quarter. Jennison Associates LLC now owns 1,273,779 shares of the biopharmaceutical company’s stock worth $11,400,000 after buying an additional 515,029 shares in the last quarter. Finally, Trexquant Investment LP boosted its stake in shares of Chimerix by 453.5% in the fourth quarter. Trexquant Investment LP now owns 131,184 shares of the biopharmaceutical company’s stock worth $1,174,000 after buying an additional 107,484 shares in the last quarter.
Chimerix, Inc (Chimerix) is a biopharmaceutical company. The Company is focused on discovering, developing and commercializing oral antivirals. The Company, based on its lipid conjugate technology, has developed its lead compound, brincidofovir (BCV, CMX001), which is in Phase III clinical development.
Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.